摘要
背景:最近,羟基酪醇对急性肺损伤(ALI)中自噬的影响越来越受到重视。 目的:探讨羟基酪醇通过上调自噬在鼠ALI鼠模型中发挥其抗炎作用的潜在分子机制。 方法:用LPS刺激鼻内注射的雄性BALB / c小鼠在LPS暴露前1小时用或不用羟基酪醇(HT,100mg / kg,胃内)处理。二十四小时后,获得肺和支气管肺泡灌洗液(BAL)液体样品,用于测定BAL液中肺湿重与干重(W / D)比,蛋白质渗漏水平和炎症细胞的差异计数。 通过蛋白质印迹和染色方法检测LPS诱导的细胞因子活性,炎症因子水平,抗衰老(SIRT1 / 3/6)表达,丝裂原活化蛋白激酶(MAPK)激活和自噬标志物表达。用Sybyl / Surflex模块研究了HT与SIRT和MAPK之间的分子对接。 结果:LPS刺激的SIRT抑制,MAPK磷酸化和自噬抑制均被HT给药显着消除。HT治疗使得BAL液中肺W / D比值与蛋白质浓度和炎症细胞水平的降低,表明治疗减弱肺水肿和炎症细胞浸润到肺组织中。HT强烈调控炎症介质的LPS驱动释放,包括TNF-α,IL-1β,IL-6,IL-10和MCP-1。 结论:HT对ALI小鼠肺部炎症的保护作用可能归因于促进自噬,这可能与SIRT / MAPK信号通路的激活有关。重要的是,本研究提供了对HT的分子机制及其治疗急性呼吸窘迫综合征治疗潜力的新见解。
关键词: 羟脯氨酸,脂多糖,自噬,抗衰老,急性肺损伤,呼吸窘迫综合征
Current Molecular Medicine
Title:Hydroxytyrosol Attenuates LPS-Induced Acute Lung Injury in Mice by Regulating Autophagy and Sirtuin Expression
Volume: 17 Issue: 2
关键词: 羟脯氨酸,脂多糖,自噬,抗衰老,急性肺损伤,呼吸窘迫综合征
摘要: Background: Recently, the effects of hydroxytyrosol on autophagy during acute lung injury (ALI) have drawn increasing attention.
Objective: We explored the underlying molecular mechanisms by which hydroxytyrosol exerts its anti-inflammatory effects in a murine model of ALI by up-regulating autophagy. Methods: Male BALB/c mice, challenged with intranasal instillations of LPS, were treated with or without hydroxytyrosol (HT, 100 mg/kg, intragastrically) 1 h prior to LPS exposure. Twenty-four hours later, lung and bronchoalveolar lavage (BAL) fluid samples were obtained for the determination of lung wet to dry weight (W/D) ratios, protein leakage levels, and differential counts of inflammatory cells in BAL fluid. LPS-induced cytokine activity, inflammatory factor levels, sirtuin (SIRT1/3/6) expression, mitogenactivated protein kinase (MAPK) activation, and autophagy marker expression in ALImice were examined by western blotting and staining methods. Molecular docking between HT and SIRT and MAPK was studied with a Sybyl/Surflex module. Results: LPS-stimulated SIRT inhibition, MAPK phosphorylation, and autophagy suppression were all notably abolished by HT administration. HT treatment significantly attenuated pulmonary edema and inflammatory cell infiltration into lung tissues, accompanied by decreased lung W/D ratios, protein concentrations, and inflammatory cell levels in BAL fluid. LPS driven release of inflammatory mediators, including TNF-α, IL-1β, IL-6, IL-10, and MCP-1, was strongly regulated by HT. Conclusions: The protective effect of HT on lung inflammation in ALI mice may be attributed to the promotion of autophagy, which is likely associated with the activation of the SIRT/MAPK signaling pathway. Importantly, this study provides new insight into the molecular mechanisms of HT and its therapeutic potential in the treatment of acute respiratory distress syndrome.Export Options
About this article
Cite this article as:
Hydroxytyrosol Attenuates LPS-Induced Acute Lung Injury in Mice by Regulating Autophagy and Sirtuin Expression, Current Molecular Medicine 2017; 17 (2) . https://dx.doi.org/10.2174/1566524017666170421151940
DOI https://dx.doi.org/10.2174/1566524017666170421151940 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Alzheimers Disease: Symptomatic and Disease-Modifying Approaches
Current Aging Science Intraarticular Treatments for Osteoarthritis: New Perspectives
Current Drug Targets Prospective Evaluation of the Dosing Regimen of Vancomycin in Children of Different Weight Categories
Current Drug Safety Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Current Drug Therapy An Overview on COVID-19 and its Effect on Cardiovascular Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Oxidative Damage Impact on Aging and Age-Related Diseases: Drug Targeting of Telomere Attrition and Dynamic Telomerase Activity Flirting with Imidazole-Containing Dipeptides
Recent Patents on Drug Delivery & Formulation Medicinal Agents in the Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Inflammation in Peripheral Arterial Disease (PAD)
Current Pharmaceutical Design Stem Cells: Clinical Trials Results The End of the Beginning or the Beginning of the End?
Cardiovascular & Hematological Disorders-Drug Targets Protease Inhibitor Monotherapy as Maintenance Regimen in Patients With HIV Infection
Current HIV Research Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Patent Selections
Recent Patents on DNA & Gene Sequences An Update on “Selenium Containing Compounds from Poison to Drug Candidates: A Review on the GPx-like Activity”
Current Chemical Biology Complement C4A and C4B Gene Copy Number Study in Alzheimer's Disease Patients
Current Alzheimer Research Desensitization for Drug Hypersensitivity to Chemotherapy and Monoclonal Antibodies
Current Pharmaceutical Design Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Mentha L. Species (Lamiaceae) as Promising Sources of Bioactive Secondary Metabolites
Current Pharmaceutical Design